Ernexa Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Aug 4, 2017 and accepted by EDGAR at Aug 4, 2017, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Selling, general and administrative | 3 months2017-04-01 to 2017-06-30 | $3.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-01-01 to 2017-06-30 | $8.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | −$26.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | −$860.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-04-01 to 2017-06-30 | $6.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | −$164.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | −$254.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2017-01-01 to 2017-06-30 | $2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $339.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-06-30 | $6.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $12.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $18.5m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $11.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $12.5m | us-gaap:Liabilities |
| Current portion of debt | At period end2017-06-30 | $5.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-06-30 | $6.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-17-008543. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.